Chemo Free or Chemo First Navigating Lu-PSMA-617, Radium, and Treatment Sequencing

The Road Ahead: Molecular Profiling, Novel Agents, and Quality-of-Life Considerations

Access, Tolerability, and Trial Limitations: Practical Decision-Making in CRPC

Evolving Standards: Triplet Therapy and the Role of Bone-Directed Agents

Therapy Buckets in Practice: Personalizing Treatment Pathways in Advanced Prostate Cancer

Identifying High-Risk Patients: Predictors of Progression to CRPC

From Tumor Boards to Trials: Evolving Approaches in Oligometastatic Prostate Cancer

Upfront Testing and Monitoring: Practical Approaches in Metastatic Prostate Cancer

Next Steps for EV/Pembro: Toxicity Management, ctDNA, and Emerging Trials

When to Scale Back: Insights from an Ongoing EV/Pembro De-Escalation Pilot Study

De-Escalation Strategies with EV/Pembro: Clinical Rationale and Evidence

Looking Ahead: Gaps, Hurdles, and Transition in Current Phase 2 RLT Trial Landscape

Key Trends in Ongoing Phase 2 RLT Trials

Expanding the Reach: TAR-200 in Papillary Disease and Beyond

Combination Therapy in SunRISe-1: Lessons from Cetrelimab and TAR-200

Primary vs Nodal Response: What Discordance Means for Surgical Planning

Robotic vs Open Cytoreductive Cystectomy: Lessons from Early Experience

Stopping Systemic Therapy: When Surgery Enables a Treatment Holiday

Cytoreductive Cystectomy After EV-302: How We Got Here

HRD Signatures, PARP, and Radiation: Where Science Meets Practice

Emerging Frontiers: T-Cell Engagers, Radioligands, and BCR

Balancing ARPI Use, PSA Response, and Genomics in Treatment Planning

Radium-223 vs Lu-PSMA-617: Evolving Roles in Bone-Predominant mCRPC

Choosing the Right ARPI: Clinical and Practical Considerations

High-Volume Disease in the PSMA-PET Era: Trials, Imaging, and Real-World Decisions

Upfront Treatment Strategies for De Novo Metastatic Prostate Cancer

Advancing Therapies for Chromophobe RCC: KIT as a Gateway for Targeted Drug Delivery

The Future of NMIBC Treatment: Going Beyond the Standard of Care Through Shared Decision Making

ENVISION Trial Update: Integrating a New Treatment into NMIBC Standard of Care

Redefining Treatment in Intermediate-Risk NMIBC: Navigating an Evolving Landscape

Perioperative Advances and ctDNA: The Next Frontier in Metastatic Bladder Cancer

Platinum Rechallenge, Immunotherapy, and Evidence Gaps in Metastatic Bladder Cancer

Breaking the Platinum Ceiling: Key Insights in Advanced Bladder Cancer

Efficacy and Durability of Response in SunRISe-1

TAR-200 in Focus: Early Experience and Patient Impact

How Trials and Targeted Therapies Are Reshaping Prostate Cancer Care

Abiraterone, Enzalutamide, Darolutamide, and Apalutamide: How Oncologists Decide

Defining Low vs High Volume: STAMPEDE and PEACE-1 Guiding Practice

Evolving Technologies vs Practical Biomarkers in Prostate Cancer Management

Early-Stage Prostate Cancer Workup: Imaging, Genomics, and Patient Health

Reflections and Road Ahead: Excitement in Prostate Cancer Care

PSMAfore in Practice: Patient Preferences, Imaging, and Sequencing Decisions

Expanding Options in mCRPC: PARP Inhibitors, Immunotherapy, and Radioligands

MDT in Practice: Balancing Systemic and Local Approaches

Selecting the Right Regimen: Insights from PEACE-1, ARASENS, and ARANOTE

Managing Post-Prostatectomy PSA Persistence and BCR

PSA to PSMA: Redefining the Prostate Cancer Diagnostic Pathway

The Future of Prostate Cancer Care: Toward a Cure and Personalized Medicine

Integrating Lutetium-177, Precision Medicine in Advanced Prostate Cancer Care

Managing Side Effects and Timing of Radium-223, PARP Inhibitors

Evolving Treatment Paradigms: From Oligometastatic Management to Combination Therapies

From Scans to Strategy: Imaging and Risk Assessment in Advanced Prostate Cancer

Barriers and Benefits of Germline Testing in Prostate Cancer Care

Globalizing the Breakthroughs: The Next Chapter in Hereditary Kidney Cancer

Metabolism Meets Medicine: A New Era for Hereditary Kidney Cancer Treatment

MAIC Evidence: Enzalutamide Versus Darolutamide in ARCHES and ARANOTE

Associations Between DDR Gene Alterations, Molecular Subtypes, and Survival Outcomes in mUC

De-escalation Without Compromise: Practical Strategies for Community Oncologists

Treating Smarter, Not Harder: Who Really Needs Lifelong ADT?

Next-Gen Targets and Therapies: From PARPs to Radioligands and ADCs